logo
Alberta AG reports cite child care overpayments, millions in ineligible pandemic payments

Alberta AG reports cite child care overpayments, millions in ineligible pandemic payments

Yahoo3 days ago
Alberta's auditor general has found that parents may have overpaid for child care due to a lack of provincial oversight of its subsidy program, and, that a pandemic assistance program for small businesses may have distributed more than $155 million to ineligible applicants.
Auditor General Doug Wylie separately released on Thursday a performance audit of the Child Care Subsidy and Grants Program, and an assessment of how the province had implemented its Small and Medium Enterprise Relaunch Grant Program.
The child care audit reported on how $1.1 billion in public funding was managed within the program during 2023-2024.
The audit found that the department didn't consistently ensure claims from operators were supported or that funding from subsidies and grants were used to reduce parents fees and pay educators.
'There is a risk of overpayment by the department and a risk that parents are overpaying for child care and educators are being under compensated,' Wylie stated in a news release.
'Albertans should have confidence that these funds are achieving the program's purpose — to reduce child care costs for families and support educators.'
Fourteen of 25 operators sampled in a single month had at least one discrepancy, and three had more significant issues including one instance where an overstated claim led to an overpayment by the department of more than $26,000 for that month.
Wylie also noted the program had been administered by three different ministries in as many years, leading to 'significant delays' in completing his report.
Postmedia has sought comment from the office of Education and Childcare Minister Demetrios Nicolaides.
In a statement, Opposition children and family services critic Diana Batten accused the government of short-changing parents and also noted the province's April cancellation of its income-tested subsidy that some parents say has sent child care costs skyrocketing.
'Smith and her uncaring government have delivered a double hit to parents struggling to afford child care, making it even more expensive. It's a failure to live up to their responsibility, improper management of public funds, and it's just cruel.'
Pandemic program overpaid $158M: Auditor general
A second report from Wylie's office follows-up on a 2022 audit of the provincial program designed to help businesses affected by pandemic public health measures. The auditor general then recommended that the government take steps to verify the eligibility of those who received funding.
Thursday's report estimates that following that verification process by the government an estimated $158 million in ineligible program payments had been made. The department projects the value of ineligible payments was significantly lower, at between $52.5 million and $105 million.
'Program effectiveness should not only be measured by getting money out the door quickly, but also by whether the program achieves its intended results,' Wylie stated in a news release.
He noted the department had focused on high-risk eligibility verifications but believed further post-payment verifications of other applications would produce diminishing returns.
'Without completing that analysis, the department would not be able to conclude on the eligibility of the majority of program applications,' he wrote in recommending further processes to verify eligibility.
The report states the ministry of Jobs, Economy, Trade and Immigration is in the process of recovering $7.6 million of payments to identified ineligible, overpaid, and non-responder recipients, and that $1.4 million has been recovered so far.
Postmedia has sought comment from the office of Jobs, Economy, Trade and Immigration Minister Joseph Schow.
mblack@postmedia.com
Bookmark our website and support our journalism: Don't miss the news you need to know — add EdmontonJournal.com and EdmontonSun.com to your bookmarks and sign up for our newsletters here.
You can also support our journalism by becoming a digital subscriber. Subscribers gain unlimited access to The Edmonton Journal, Edmonton Sun, National Post and 13 other Canadian news sites. Support us by subscribing today: The Edmonton Journal | The Edmonton Sun.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stellantis Takes $350 Million Hit From Tariffs
Stellantis Takes $350 Million Hit From Tariffs

Wall Street Journal

time12 minutes ago

  • Wall Street Journal

Stellantis Takes $350 Million Hit From Tariffs

Stellantis's STLA -2.23%decrease; red down pointing triangle earnings took a hit of around $350 million from U.S. tariffs, while restructuring efforts and higher costs also dragged on the Jeep maker's results. The carmaker on Monday said it swung to a net loss in the first half of the year, as it booked 300 million euros ($348.8 million) of net costs from the early effects of the tariffs that include the loss of planned production.

AlgoFusion 5.0: Inside AlgoFusion 5.0's Latency Engine for Execution Precision
AlgoFusion 5.0: Inside AlgoFusion 5.0's Latency Engine for Execution Precision

Associated Press

time37 minutes ago

  • Associated Press

AlgoFusion 5.0: Inside AlgoFusion 5.0's Latency Engine for Execution Precision

NEW YORK, July 21, 2025 /PRNewswire/ -- AlgoFusion 5.0 has launched a specialized update focused on execution timing analytics, addressing one of the most critical yet under-measured dimensions of algorithmic trading: latency. The platform now enables users to monitor, visualize, and optimize the time elapsed between signal generation and trade execution, offering a granular view of strategy responsiveness across asset classes and timeframes. At the heart of this release is the new Execution Timing Suite, which introduces live dashboards, timestamped logic chains, and latency heatmaps, giving users a detailed perspective into how their strategies perform under real-market conditions. Unlike conventional performance metrics that focus on outcomes, this suite measures behavioral speed, exposing bottlenecks that can compromise timing-sensitive strategies. Core features in this release include: These new capabilities address the needs of multiple user profiles. For systematic traders, the suite allows for the refinement of high-frequency strategies. Discretionary managers gain insights into the factors contributing to suboptimal trade timing. Infrastructure teams benefit from increased visibility into how platform conditions influence operational performance. The execution timing tools are fully integrated into AlgoFusion's existing visual strategy builder, allowing users to view timing performance alongside logic flow, risk parameters, and outcome metrics. This makes it possible to optimize strategies holistically—balancing speed, structure, and statistical effectiveness. 'Latency is not just a technical detail—it's a competitive variable,' said Marcus Leighton, Head of Product Strategy at AlgoFusion. 'With this release, we're helping users understand how their systems behave in motion, not just in logic.' In addition to live trading environments, the Execution Timing Suite is available in simulation and backtest modes, making it a valuable resource for education, prototyping, and infrastructure benchmarking. Users can export time series data, generate reports for compliance or governance review, and benchmark multiple strategies against timing stability scores. This release aligns with AlgoFusion's broader objective to enhance the measurability, transparency, and execution-awareness of automated trading, supporting users in the development and deployment of data-driven strategies. About AlgoFusion 5.0 AlgoFusion 5.0 is a modular, multi-asset strategy platform designed to empower traders, analysts, and institutions with transparent automation tools. The system features visual logic construction, real-time performance tracking, explainability frameworks, and integrated diagnostics. Whether for live execution, simulation, or collaborative development, AlgoFusion 5.0 provides a high-resolution view into how strategies behave across conditions, timeframes, and infrastructures. Users Can Explore Execution Timing Tools in AlgoFusion 5.0: Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended that users practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Contact Travis Morgan AlgoFusion [email protected] Photo: View original content to download multimedia: SOURCE AlgoFusion 5.0

Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board

Associated Press

time37 minutes ago

  • Associated Press

Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board

VANCOUVER, BC / ACCESS Newswire / July 21, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce the appointment of Dr. Dennis Hall, Professor of Chemistry at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Hall is internationally recognized for his pioneering work in organoboron chemistry, catalysis, and medicinal chemistry, including the development of DNA repair inhibitors. He currently holds the Tier 1 Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, and leads a multidisciplinary research team dedicated to the development of novel synthetic and biological applications of boron-containing compounds.[1] With over 175 peer-reviewed publications, two books, and 15 book chapters, Dr. Hall's contributions span catalysis, heterocyclic chemistry, and medicinal chemistry. He has mentored more than 75 graduate students and postdoctoral fellows, and his work has been widely cited with over 18,000 citations and an h-index of 70.[2] Among his numerous accolades are the Arthur C. Cope Scholar Award (2024) from the American Chemical Society[3], the R. U. Lemieux Award (2021) from the Canadian Society for Chemistry[4], and a Killam Research Fellowship (2019-2021). He was elected a Fellow of the Royal Society of Canada in 2017. [5] As part of his role, Dr. Hall will serve on the Scientific and Clinical Advisory Board and provide strategic advice to the Company on its Research and Development agenda, including clinical discovery, synthesis and manufacturing, pre-clinical testing, and clinical translation plans associated with Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. He will also collaborate with the Company's scientific and clinical leadership, as well as external partners, to advance oncology-focused innovations. 'Dr. Hall's appointment marks a significant step in bridging advanced synthetic chemistry with translational oncology. His expertise in boron-based drug discovery is uniquely aligned with our mission to develop precision therapies, and we look forward to leveraging his insight as we push our PNKP Inhibitor Technology toward the clinic,' stated Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. [1] [2] [3] [4] [5] SOURCE: Onco-Innovations Limited press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store